Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia-Reference-Cited by-同舟云学术

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia

Published:2017-04-20 Issue:16 Volume:129 Page:2330-2332
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Godwin Colin D.¹,McDonald George B.²³,Walter Roland B.²⁴⁵^ORCID

Affiliation:

1. Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA;

2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and

3. Division of Gastroenterology, Department of Medicine,

4. Division of Hematology, Department of Medicine, and

5. Department of Epidemiology, University of Washington, Seattle, WA

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/16/2330/1399567/blood762419.pdf

Reference26 articles.

1. Seattle Genetics announces clinical hold on several phase 1 trials of vadastuximab talirine (SGN-CD33A). http://www.businesswire.com/news/home/20161227005087/en/. Accessed 12 January 2017.

2. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT);Mohty;Bone Marrow Transplant,2015

3. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin;Cowan;Front Biosci (Landmark Ed),2013

4. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia;Bross;Clin Cancer Res,2001

5. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project;McKoy;Leuk Res,2007

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms;Blood;2024-07-11

2. CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture;Cancers;2024-01-12

3. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability;Cancers;2023-01-24

4. The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands;International Journal of Molecular Sciences;2022-12-14

5. The use of multistage immunotherapy to achieve remission before haploidentical hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia and the treatment of complications of this therapy in the early post-transplant period: a review of the literature and a clinical case;Russian Journal of Pediatric Hematology and Oncology;2022-08-16